| A Study of Talquetamab and Teclistamab Each in Combination With a Programmed Cell Death Receptor-1 (PD-1) Inhibitor for the Treatment of Participants With Relapsed or Refractory Multiple Myeloma (NCT05338775) | Janssen Research & Development, LLC | 2022-05-25 |
| A Study to Assess the Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma Receiving Oral ABBV-453 Tablets (NCT05308654) | AbbVie | 2022-05-17 |
| Study to Evaluate the Safety, Tolerance, Pharmacokinetics and Preliminary Efficacy of IBI346#CIBI346Y002# (NCT05266768) | Chunrui Li | 2022-04-28 |
| Study to Evaluate the Safety, Tolerance, Pharmacokinetics and Preliminary Efficacy of IBI346#CIBI346Y001# (NCT05270928) | The First Affiliated Hospital of Soochow University | 2022-04-27 |
| A Study to Assess Adverse Events and Change in Disease State of Intravenously (IV) Infused Etentamig (ABBV-383) of Adult Participants With Relapsed or Refractory Multiple Myeloma in Japan (NCT05286229) | AbbVie | 2022-03-24 |
| A Study of CAR-GPRC5D in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia (NCT05219721) | Chunrui Li | 2022-03-17 |
| Long-Term Follow-up Study (NCT05332054) | Caribou Biosciences, Inc. | 2022-03-16 |
| Belantamab Mafodotin, Cyclophosphamide, and Dexamethasone in Relapsed/Refractory Multiple Myeloma (NCT04896658) | University of Maryland, Baltimore | 2021-12-03 |
| A Study of Real-Life Current Standards of Care in Participants With Relapsed and/or Refractory Multiple Myeloma (NCT05160584) | Janssen Pharmaceutica N.V., Belgium | 2021-11-18 |
| A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma (NCT04973605) | BeOne Medicines | 2021-09-16 |
| agenT-797 in Participants With Relapsed/Refractory Multiple Myeloma (NCT04754100) | MiNK Therapeutics | 2021-03-29 |
| Sub-study of Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Dostarlimab (GSK4057190) in Participants With RRMM (NCT06655818) | GlaxoSmithKline | 2021-03-09 |
| Study of Melflufen (Melphalan Flufenamide) in Combination With Daratumumab in Relapsed-Refractory Multiple Myeloma (NCT04649060) | Oncopeptides AB | 2020-12-21 |
| RAPA-201 T Cell Therapy for Relapsed, Refractory Multiple Myeloma (NCT04176380) | Rapa Therapeutics LLC | 2020-12-02 |
| A Single-center Exploratory Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of a BCMA-targeted Universal LCAR-BCX Cells in Patients With Relapsed/Refractory Multiple Myeloma (NCT04601935) | Weijun Fu | 2020-10-09 |
| Antigen-specific T Cell Therapy for Patients With Relapsed Refractory Multiple Myeloma (NCT04505813) | NexImmune Inc. | 2020-08-17 |
| Immuno-Oncology Drugs Elotuzumab, Anti-LAG-3 and Anti-TIGIT (NCT04150965) | Multiple Myeloma Research Consortium | 2020-07-10 |
| Clinical Trial Using Humanized CART Directed Against BCMA (ARI0002h) in Patients With Relapsed/Refractory Multiple Myeloma to Proteasome Inhibitors, Immunomodulators and Anti-CD38 Antibody. (NCT04309981) | Sara V. Latorre | 2020-05-27 |
| A Dose-escalation Study to Evaluate the Safety and Clinical Activity of PBCAR269A, With or Without Nirogacestat, in Study Participants With Relapsed/Refractory Multiple Myeloma (NCT04171843) | Precision BioSciences, Inc. | 2020-04-30 |
| Study of Ipilimumab After Stem Cell Transplantation in People With Relapsed/Refractory Multiple Myeloma (NCT04635735) | Memorial Sloan Kettering Cancer Center | 2020-01-12 |
| Study Evaluating Safety and Efficacy of UCART Targeting CS1 in Patients With Relapsed/Refractory Multiple Myeloma (MELANI-01) (NCT04142619) | Cellectis S.A. | 2019-11-21 |
| Platform Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With aOX40 (GSK3174998) in Participants With RRMM (NCT06160609) | GlaxoSmithKline | 2019-10-07 |
| Safety and Efficacy of ALLO-715 BCMA Allogenic CAR T Cells in in Adults With Relapsed or Refractory Multiple Myeloma (UNIVERSAL) (NCT04093596) | Allogene Therapeutics | 2019-09-23 |
| Study to Evaluate Safety Tolerability & Efficacy of Kyprolis (Carfilzomib) in Relapsed or Refractory Multiple Myeloma (NCT03934684) | Amgen | 2019-09-16 |
| Myeloma-Developing Regimens Using Genomics (MyDRUG) (NCT03732703) | Multiple Myeloma Research Consortium | 2019-04-01 |
| Daratumumab, Ixazomib, Pomalidomide, and Dexamethasone as Salvage Therapy in Relapsed/Refractory Multiple Myeloma (NCT03590652) | University of California, San Diego | 2018-10-17 |
| Study Evaluating AMG 424 in Subjects With Multiple Myeloma (NCT03445663) | Xencor, Inc. | 2018-07-31 |
| MEDI2228 in Subjects With Relapsed/Refractory Multiple Myeloma (NCT03489525) | MedImmune LLC | 2018-05-08 |
| Cabozantinib as a Targeted Strategy to Reverse Carfilzomib Resistance in Refractory Multiple Myeloma (NCT03201250) | University of Nebraska | 2018-02-21 |
| Efficacy of Daratumumab in Patients With Relapsed/Refractory Myeloma With Renal Impairment (NCT03450057) | Hellenic Society of Hematology | 2018-02-15 |
| A Study to Assess AMG 701 Montherapy, or in Combination With Pomalidomide, With or Without, Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma (NCT03287908) | Amgen | 2017-11-13 |
| Study of ISB 1342, a CD38/CD3 Bispecific Antibody, in Subjects With Previously Treated Multiple Myeloma (NCT03309111) | Ichnos Sciences SA | 2017-10-25 |
| Study to Evaluate the Safety and Efficacy of KITE-585 in Participants With Relapsed/Refractory Multiple Myeloma (NCT03318861) | Kite, A Gilead Company | 2017-10-20 |
| Safety and Pharmacokinetics of Rising Doses of APO010 in Relapsed/Refractory Multiple Myeloma Patients Selected by DRP (NCT03196947) | Allarity Therapeutics | 2017-06-13 |
| NINLARO Capsules Drug Use-Results Survey (All-Case Surveillance) "Relapsed/Refractory Multiple Myeloma" (NCT03169361) | Takeda | 2017-05-24 |
| A Study Evaluating Venetoclax (ABT-199) in Multiple Myeloma Subjects Who Are Receiving Bortezomib and Dexamethasone as Standard Therapy (NCT02755597) | AbbVie | 2016-07-11 |
| A Retrospective Chart Review Study of the Outcomes of 2nd Line Therapy With LEn/Dex in Greek Patients With R/R Multiple MyEloma and the Treatment PatterNs Following Progressive Disease (NCT02608515) | Genesis Pharma S.A. | 2015-12-01 |
| A Study Evaluating ABT-199 in Multiple Myeloma Subjects Who Are Receiving Bortezomib and Dexamethasone as Standard Therapy (NCT01794507) | AbbVie | 2012-11-19 |
| Study Evaluating ABT-199 in Participants With Relapsed or Refractory Multiple Myeloma (NCT01794520) | AbbVie | 2012-10-10 |
| Aplidin - Dexamethasone in Relapsed/Refractory Myeloma (NCT01102426) | PharmaMar | 2010-06-01 |
| Reduced Intensity Conditioning With Clofarabine, Antithymocyte Globulin (ATG), Total Lymphoid Irradiation (TLI) Followed by Allogeneic Stem Cell Transplant (NCT00697684) | Beth Israel Deaconess Medical Center | 2008-06-01 |